259 related articles for article (PubMed ID: 35654037)
1. Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson's disease.
Panicker N; Kam TI; Wang H; Neifert S; Chou SC; Kumar M; Brahmachari S; Jhaldiyal A; Hinkle JT; Akkentli F; Mao X; Xu E; Karuppagounder SS; Hsu ET; Kang SU; Pletnikova O; Troncoso J; Dawson VL; Dawson TM
Neuron; 2022 Aug; 110(15):2422-2437.e9. PubMed ID: 35654037
[TBL] [Abstract][Full Text] [Related]
2. Parkin regulates microglial NLRP3 and represses neurodegeneration in Parkinson's disease.
Yan YQ; Zheng R; Liu Y; Ruan Y; Lin ZH; Xue NJ; Chen Y; Zhang BR; Pu JL
Aging Cell; 2023 Jun; 22(6):e13834. PubMed ID: 37029500
[TBL] [Abstract][Full Text] [Related]
3. Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease.
Han X; Sun S; Sun Y; Song Q; Zhu J; Song N; Chen M; Sun T; Xia M; Ding J; Lu M; Yao H; Hu G
Autophagy; 2019 Nov; 15(11):1860-1881. PubMed ID: 30966861
[TBL] [Abstract][Full Text] [Related]
4. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice.
Gordon R; Albornoz EA; Christie DC; Langley MR; Kumar V; Mantovani S; Robertson AAB; Butler MS; Rowe DB; O'Neill LA; Kanthasamy AG; Schroder K; Cooper MA; Woodruff TM
Sci Transl Med; 2018 Oct; 10(465):. PubMed ID: 30381407
[TBL] [Abstract][Full Text] [Related]
5. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration.
Lee E; Hwang I; Park S; Hong S; Hwang B; Cho Y; Son J; Yu JW
Cell Death Differ; 2019 Jan; 26(2):213-228. PubMed ID: 29786072
[TBL] [Abstract][Full Text] [Related]
6. NLRP3 Inflammasomes in Parkinson's disease and their Regulation by Parkin.
Yan YQ; Fang Y; Zheng R; Pu JL; Zhang BR
Neuroscience; 2020 Oct; 446():323-334. PubMed ID: 32795556
[TBL] [Abstract][Full Text] [Related]
7. Andrographolide suppresses NLRP3 inflammasome activation in microglia through induction of parkin-mediated mitophagy in in-vitro and in-vivo models of Parkinson disease.
Ahmed S; Kwatra M; Ranjan Panda S; Murty USN; Naidu VGM
Brain Behav Immun; 2021 Jan; 91():142-158. PubMed ID: 32971182
[TBL] [Abstract][Full Text] [Related]
8. p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson's disease.
Chen J; Mao K; Yu H; Wen Y; She H; Zhang H; Liu L; Li M; Li W; Zou F
J Neuroinflammation; 2021 Dec; 18(1):295. PubMed ID: 34930303
[TBL] [Abstract][Full Text] [Related]
9. Ellagic Acid Protects Dopamine Neurons via Inhibition of NLRP3 Inflammasome Activation in Microglia.
He XM; Zhou YZ; Sheng S; Li JJ; Wang GQ; Zhang F
Oxid Med Cell Longev; 2020; 2020():2963540. PubMed ID: 33294118
[TBL] [Abstract][Full Text] [Related]
10. Perillyl Alcohol Attenuates NLRP3 Inflammasome Activation and Rescues Dopaminergic Neurons in Experimental In Vitro and In Vivo Models of Parkinson's Disease.
Ahmed S; Panda SR; Kwatra M; Sahu BD; Naidu V
ACS Chem Neurosci; 2022 Jan; 13(1):53-68. PubMed ID: 34904823
[TBL] [Abstract][Full Text] [Related]
11. NF-κB/NLRP3 inflammasome axis and risk of Parkinson's disease in Type 2 diabetes mellitus: A narrative review and new perspective.
Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Jabir MS; Saad HM; Batiha GE
J Cell Mol Med; 2023 Jul; 27(13):1775-1789. PubMed ID: 37210624
[TBL] [Abstract][Full Text] [Related]
12. Targeting microglial NLRP3 in the SNc region as a promising disease-modifying therapy for Parkinson's disease.
Qiao C; Dang T; Zhou Y; Zhou YZ; Zhao R; Wang M
Brain Behav; 2022 Nov; 12(11):e2784. PubMed ID: 36199191
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease.
Zhou Y; Lu M; Du RH; Qiao C; Jiang CY; Zhang KZ; Ding JH; Hu G
Mol Neurodegener; 2016 Apr; 11():28. PubMed ID: 27084336
[TBL] [Abstract][Full Text] [Related]
14. Trib3 Is Elevated in Parkinson's Disease and Mediates Death in Parkinson's Disease Models.
Aimé P; Sun X; Zareen N; Rao A; Berman Z; Volpicelli-Daley L; Bernd P; Crary JF; Levy OA; Greene LA
J Neurosci; 2015 Jul; 35(30):10731-49. PubMed ID: 26224857
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP/p mouse model of Parkinson's disease.
Qiao C; Zhang Q; Jiang Q; Zhang T; Chen M; Fan Y; Ding J; Lu M; Hu G
J Neuroinflammation; 2018 Jul; 15(1):193. PubMed ID: 29966531
[TBL] [Abstract][Full Text] [Related]
16. Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease.
Grotemeyer A; Fischer JF; Koprich JB; Brotchie JM; Blum R; Volkmann J; Ip CW
J Neuroinflammation; 2023 Mar; 20(1):79. PubMed ID: 36945016
[TBL] [Abstract][Full Text] [Related]
17. Taking the parkin brakes off of neuronal NLRP3 drives inflammasome activation and neurodegeneration in Parkinson's disease.
Zengeler KE; Lukens JR
Neuron; 2022 Aug; 110(15):2356-2358. PubMed ID: 35926449
[TBL] [Abstract][Full Text] [Related]
18. NLRP3 Inflammasome Inhibition Prevents α-Synuclein Pathology by Relieving Autophagy Dysfunction in Chronic MPTP-Treated NLRP3 Knockout Mice.
Ou Z; Zhou Y; Wang L; Xue L; Zheng J; Chen L; Tong Q
Mol Neurobiol; 2021 Apr; 58(4):1303-1311. PubMed ID: 33169332
[TBL] [Abstract][Full Text] [Related]
19. Hyperoside suppresses NLRP3 inflammasome in Parkinson's disease via Pituitary Adenylate Cyclase-Activating Polypeptide.
Wang K; Lu C; Wang T; Qiao C; Lu L; Wu D; Lu M; Chen R; Fan L; Tang J
Neurochem Int; 2022 Jan; 152():105254. PubMed ID: 34883151
[TBL] [Abstract][Full Text] [Related]
20. PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency.
Pirooznia SK; Yuan C; Khan MR; Karuppagounder SS; Wang L; Xiong Y; Kang SU; Lee Y; Dawson VL; Dawson TM
Mol Neurodegener; 2020 Mar; 15(1):17. PubMed ID: 32138754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
